Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 125

1.

Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.

Bakish D, Bose A, Gommoll C, Chen C, Nunez R, Greenberg WM, Liebowitz M, Khan A.

J Psychiatry Neurosci. 2014 Jan;39(1):40-9. doi: 10.1503/jpn.130040.

PMID:
24144196
[PubMed - in process]
Free PMC Article
2.

A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder.

Sambunaris A, Bose A, Gommoll CP, Chen C, Greenberg WM, Sheehan DV.

J Clin Psychopharmacol. 2014 Feb;34(1):47-56. doi: 10.1097/JCP.0000000000000060.

PMID:
24172209
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study.

Asnis GM, Bose A, Gommoll CP, Chen C, Greenberg WM.

J Clin Psychiatry. 2013 Mar;74(3):242-8. doi: 10.4088/JCP.12m08197.

PMID:
23561229
[PubMed - indexed for MEDLINE]
Free Article
4.

Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.

Montgomery SA, Mansuy L, Ruth A, Bose A, Li H, Li D.

J Clin Psychiatry. 2013 Apr;74(4):363-9. doi: 10.4088/JCP.12m08141.

PMID:
23656841
[PubMed - indexed for MEDLINE]
Free Article
5.

Evaluation of functional health and well-being in patients receiving levomilnacipran ER for the treatment of major depressive disorder.

Blum SI, Tourkodimitris S, Ruth A.

J Affect Disord. 2015 Jan;170:230-6. doi: 10.1016/j.jad.2014.09.005. Epub 2014 Sep 10.

PMID:
25259674
[PubMed - in process]
Free Article
6.

The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study.

Montgomery SA, Mansuy L, Ruth AC, Li D, Gommoll C.

Int Clin Psychopharmacol. 2014 Jan;29(1):26-35. doi: 10.1097/YIC.0000000000000009.

PMID:
24172160
[PubMed - indexed for MEDLINE]
Free PMC Article
7.
8.
9.

Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.

Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D.

Clin Ther. 2009 Jun;31 Pt 1:1405-23. doi: 10.1016/j.clinthera.2009.07.006.

PMID:
19698901
[PubMed - indexed for MEDLINE]
10.

[Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].

OliƩ JP, Gourion D, Montagne A, Rostin M, Poirier MF.

Encephale. 2009 Dec;35(6):595-604. doi: 10.1016/j.encep.2009.10.011. Epub . French.

PMID:
20004291
[PubMed - indexed for MEDLINE]
11.

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.

J Clin Psychiatry. 2004 Oct;65(10):1356-64.

PMID:
15491239
[PubMed - indexed for MEDLINE]
12.

Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial.

Croft HA, Pomara N, Gommoll C, Chen D, Nunez R, Mathews M.

J Clin Psychiatry. 2014 Nov;75(11):e1291-8. doi: 10.4088/JCP.14m08992.

PMID:
25470094
[PubMed - indexed for MEDLINE]
Free Article
13.

Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials.

Montgomery SA, Gommoll CP, Chen C, Greenberg WM.

CNS Spectr. 2014 Jun 5:1-9. [Epub ahead of print]

PMID:
24902007
[PubMed - as supplied by publisher]
14.

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.

Eur Neuropsychopharmacol. 2004 Dec;14(6):457-70.

PMID:
15589385
[PubMed - indexed for MEDLINE]
15.

A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder.

Liebowitz MR, Yeung PP, Entsuah R.

J Clin Psychiatry. 2007 Nov;68(11):1663-72.

PMID:
18052559
[PubMed - indexed for MEDLINE]
16.
17.

A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.

Gaynor PJ, Gopal M, Zheng W, Martinez JM, Robinson MJ, Marangell LB.

Curr Med Res Opin. 2011 Oct;27(10):1849-58. doi: 10.1185/03007995.2011.609539. Epub 2011 Aug 12.

PMID:
21838411
[PubMed - indexed for MEDLINE]
19.

A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder.

Wang G, McIntyre A, Earley WR, Raines SR, Eriksson H.

Neuropsychiatr Dis Treat. 2014 Jan 30;10:201-16. doi: 10.2147/NDT.S50248. eCollection 2014.

PMID:
24511235
[PubMed]
Free PMC Article
20.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk